Literature DB >> 34705051

A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology.

Chiara Gasteiger1, Urte Scholz2,3, Keith J Petrie4, Nicola Dalbeth5,6.   

Abstract

Patient perceptions influence biosimilar uptake in non-mandatory transitions. Companions (support people) are often actively involved in the patient's medical journey and are likely to have unique perceptions of biosimilars, which may shape patient attitudes. This study explores the congruence between patient and companion perceptions towards biosimilars and their information needs. Patients taking bio-originators for rheumatic diseases (59% for rheumatoid arthritis) and their companions received an explanation about biosimilars. Participants (N = 78) completed questionnaires assessing their familiarity with biosimilars, perceptions, concerns, and benefits of being accompanied. Contingency tables and paired sample t-tests were used to explore differences in familiarity, confidence in knowledge, and perceptions. Intra-class correlation coefficients were calculated to assess the degree of congruence for perceptions towards biosimilars. Companions were significantly less familiar with biosimilars (p = 0.014, Cramer's V = 0.28) and reported lower confidence in their knowledge (p = 0.006, Cohen's d = 0.47) than patients. Companions and patients had moderate to good congruency for perceptions toward confidence in biosimilar use and safety, efficacy, and side-effect expectations (intra-class correlation coefficients ranging from 0.75 to 0.81). Companions and patients were most concerned about safety and effectiveness. Companions also reported concerns about cost savings driving the transition, while patients had concerns about uncertainty and testing. Patients reported the ability for discussion, improved understanding, and validation as benefits of being accompanied. Companions and patients have similar levels of perceptions and expectations towards biosimilars but report some unique information needs. Future educational interventions should involve companions and address their concerns to help improve biosimilar acceptance.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biologics; Biosimilars; Decision-making; Follow-on biologics; Support person

Mesh:

Substances:

Year:  2021        PMID: 34705051     DOI: 10.1007/s00296-021-05037-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  30 in total

Review 1.  Family presence in routine medical visits: a meta-analytical review.

Authors:  Jennifer L Wolff; Debra L Roter
Journal:  Soc Sci Med       Date:  2011-02-24       Impact factor: 4.634

2.  Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

Authors:  Vincent Germain; Marc Scherlinger; Thomas Barnetche; Thierry Schaeverbeke
Journal:  Ann Rheum Dis       Date:  2018-10-23       Impact factor: 19.103

3.  Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.

Authors:  Laurent Peyrin-Biroulet; Sanna Lönnfors; Xavier Roblin; Silvio Danese; Luisa Avedano
Journal:  J Crohns Colitis       Date:  2016-07-31       Impact factor: 9.071

4.  Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.

Authors:  Eline van Overbeeke; Birgit De Beleyr; Jan de Hoon; Rene Westhovens; Isabelle Huys
Journal:  BioDrugs       Date:  2017-10       Impact factor: 5.807

5.  Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.

Authors:  Lieke Tweehuysen; Bart J F van den Bemt; Iris L van Ingen; Alphons J L de Jong; Willemijn H van der Laan; Frank H J van den Hoogen; Alfons A den Broeder
Journal:  Arthritis Rheumatol       Date:  2017-12-07       Impact factor: 10.995

6.  Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis.

Authors:  Tom Kovitwanichkanont; Sudha Raghunath; Dorothy Wang; Leo Kyi; Silvana Pignataro; Susan Morton; Eric Morand; Michelle Leech
Journal:  Intern Med J       Date:  2020-03       Impact factor: 2.048

Review 7.  Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.

Authors:  Mourad F Rezk; Burkhard Pieper
Journal:  Rheumatol Ther       Date:  2017-10-14

8.  The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.

Authors:  Johlee S Odinet; Chelsea E Day; Jennifer L Cruz; Gregory A Heindel
Journal:  J Manag Care Spec Pharm       Date:  2018-10

9.  To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.

Authors:  Mourad F Rezk; Burkhard Pieper
Journal:  Adv Ther       Date:  2018-06-05       Impact factor: 3.845

10.  Biosimilar Uptake: The Importance of Healthcare Provider Education.

Authors:  Sonia Tadjalli Oskouei; Andrew R Kusmierczyk
Journal:  Pharmaceut Med       Date:  2021-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.